Basic principles of rapid neuroleptization.
D000978:Antiparkinson Agents / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy; D002746:Chlorpromazine / Q000009:adverse effects / Q000627:therapeutic use; D005476:Fluphenazine / Q000008:administration & dosage; D006220:Haloperidol / Q000008:administration & dosage / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D007024:Hypotension, Orthostatic / Q000628:therapy; D008487:Medical History Taking; D011605:Psychoses, Substance-Induced / Q000188:drug therapy; D011618:Psychotic Disorders / Q000188:drug therapy*; D013888:Thiothixene / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D014149:Tranquilizing Agents; D013888:Thiothixene; D006220:Haloperidol; D005476:Fluphenazine; D002746:Chlorpromazine